Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350157 | 0.86 | CYP2C19 (0.75) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL28997199 | 0.84 | CYP2C19 (0.72) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL4371675 | 0.84 | CYP2C19 (0.72) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL8434543 | 0.84 | CYP2C19 (0.72) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL253781 | 0.84 | CYP2C19 (0.72) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL934056 | 0.83 | CYP2C19 (0.70) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL43293 | 0.82 | CYP2C19 (0.70) | CYP2C19RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL16683907 | 0.82 | CYP2C19 (0.70) | CYP2C19LMNARAB9ASLC1A3SLC1A2 | |
| SCHEMBL288244 | 0.82 | CYP2C19 (0.70) | CYP2C19RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9402288 | 0.82 | CYP2C19 (0.70) | CYP2C19LMNARAB9ASLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009084028-A2 | IMPROVED PROCESS FOR MANUFACTURING ANHYDROUS (E)-3-[2-BUTYL-1- {(4-CARBOXYPHENYL) METHYL}-1H-IMIDAZOLE-5-YL]-(THIOPHEN-2- YLMETHYL)PROP-2-ENOIC ACID METHANE SULFONATE | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | claimed |
| CN-105209453-B | The quinolyl conditioning agent of the methylene connection of ROR γ T | 詹森药业有限公司 | 2017-06-20 | — | — | CN | disclosed |
| EP-2909192-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9290476-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-22 | — | — | US | disclosed |
| US-9290476-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-22 | — | — | US | disclosed |
| US-9290476-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-22 | — | — | US | disclosed |
| CN-105209453-A | Methylene linked quinolinyl modulators of ROR-gamma-T | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-17 | — | — | US | disclosed |
| WO-1997000261-A1 | PHOSPHINIC ACID DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1997-01-03 | — | — | WO | disclosed |
| US-5447949-A | Vision defects or cardiovascular disorders | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995015325-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5395847-A | Angiotensin II receptor antagonists; useful in regulating hypertension, treatment of congestive heart failure, renal failure, and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-07 | — | — | US | disclosed |
| EP-0585383-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0585383-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-09 | — | — | EP | disclosed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| US-5169841-A | Enzyme inhibitors, hypotensive agents, high enteral bioauailability | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| WO-1992020651-A2 | N-(HETEROARYL)-IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4690945-A | ANTIINFLAMMATORY AGENTS; ANALGESICS | LABORATORIOS MADAUS CERAFARM, S.A. (ES) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107094-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | CYP2C19 1510/4885LMNA 3340/4885RAB9A 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.